Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept),
a Biosimilar of Enbrel, in Korea
a Biosimilar of Enbrel, in Korea
First Product from Global
Partnership to Deliver High-Quality Biosimilars
to Help Meet Needs of Patients and Healthcare Systems Worldwide
to Help Meet Needs of Patients and Healthcare Systems Worldwide
KENILWORTH,
N.J., and SEOUL, South Korea, Sept. 8, 2015 – Merck (NYSE:MRK), known as MSD
outside the United States and Canada, and Samsung Bioepis Co., Ltd. today
announced the approval of BRENZYS™ (etanercept), a biosimilar of the immunology
medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea.
BRENZYS is indicated for the treatment of rheumatoid arthritis, psoriatic
arthritis, axial spondyloarthritis (non-radiographic axial spondyloarthritis
and ankylosing spondylitis) and psoriasis in adult patients (age 18 years and
older)
0 comentários:
Postar um comentário
Observação: somente um membro deste blog pode postar um comentário.